ライフサイエンスコーパス: vaccine

1 magnitude detected after the second dose of vaccine.

2 rogated the protective efficacy of GCP-rCpa1 vaccine.

3 developmental path for a safe and effective vaccine.

4 lated within a lipid nanoparticle (LNP) as a vaccine.

5 rscores the urgency for a safe and effective vaccine.

6 anted H5N1 avian influenza virus inactivated vaccine.

7 tance in S. Paratyphi, for which there is no vaccine.

8 ppeared following introduction of diphtheria vaccine.

9 ensed as a single-dose Japanese encephalitis vaccine.

10 sistance, and lack of a robustly efficacious vaccine.

11 ed 1 month later by 23-valent polysaccharide vaccine.

12 rapid response aiming to develop a COVID-19 vaccine.

13 hogen that still lacks a curative therapy or vaccine.

14 iral challenges compared to the wild-type H2 vaccines.

15 overy and development of new live attenuated vaccines.

16 testing and potential rollout of efficacious vaccines.

17 according to the same schedule with the same vaccines.

18 s an important hurdle in designing effective vaccines.

19 urther development as alternative SARS-CoV-2 vaccines.

20 erse symmetries towards generation of potent vaccines.

21 onable targets for antiparasite therapies or vaccines.

22 e development of SARS-CoV-2 therapeutics and vaccines.

23 influences immune responses to oral enteric vaccines.

24 s for the development of immunotherapies and vaccines.

25 e protection provided by different pertussis vaccines.

26 tocks for research and for the generation of vaccines.

27 vated measles or respiratory syncytial virus vaccines.

28 ivery and storage stability of protein-based vaccines.

29 n important measure of efficacy of drugs and vaccines.

30 tetravalent vaccine than after the trivalent vaccine (10 413 EU/mL, 95% CI 7284-14 886 in the tetrava

31 trolled trial enrolled 252 participants (210 vaccine/42 placebo; median age 23 years; 43% female) bet

32 The meningococcal group B vaccine 4CMenB is a new, recombinant protein-based vacci

33 he variability in responses to the influenza vaccine across the population.

34 We have prepared a number of saponin-based vaccine adjuvant candidates.

35 sting vector immunity and a pro-inflammatory vaccine adjuvant may influence RhCMV/SIV vaccine immunog

36 e based on anti-CD40 DNA aptamers as a novel vaccine adjuvant.

37 in IBH of horses and developed a therapeutic vaccine against equine IL-31 (eIL-31).

38 tional immune response of the elderly to the vaccine against influenza.

39 hat it is possible to develop a prophylactic vaccine against LF.

40 clinically relevant polysaccharide conjugate vaccine against Streptococcus pneumoniae (pneumococcus).

41 he development of therapeutic antibodies and vaccines against coronavirus disease 2019 (COVID-19) is

42 To date, there are no efficacious drugs and vaccines against MERS-CoV, increasing its potential to c

43 ction for antibody-based countermeasures and vaccines against SARS-CoV-2.

44 Antibody-based drugs and vaccines against severe acute respiratory syndrome coron

45 nd live mutants lead the design of canonical vaccines aimed at disrupting infection in the host.

46 Concurrent approaches, such as vaccines aiming to reduce infection incidence, are neede

47 rticipants to the adjuvanted vaccine (n=17), vaccine alone (n=16), or placebo group (n=16).

48 parameters and homologous or closely related vaccine and challenge viruses gave the best prediction o

49 An antigenic mismatch between the vaccine and circulating H3N2 strains was hypothesized to

50 inst vaccine-type CIN2+ after 3 doses of HPV vaccine and lower but significant VE with 1 or 2 doses.

51 it relies on competition between proprietary vaccines and allows the bar on safety and efficacy to be

52 arget for rational design of live attenuated vaccines and antiviral drugs.

53 sessment in light of developments in typhoid vaccines and increasing antimicrobial resistance in Salm

54 B cells induced by numerous influenza virus vaccines and infections, we found mAbs targeting conserv

55 ant 115861) and Crucell Holland (now Janssen Vaccines and Prevention B.V.), European Union's Horizon

56 te to the divergent immune responsiveness to vaccines and susceptibility to infection observed during

57 a blueprint for the development of improved vaccines and therapeutics against IBVs.

58 roteins and for the development of effective vaccines and therapeutics.

59 uld be a valuable tool for testing potential vaccines and therapeutics.

60 ment of more universal SARS-like coronavirus vaccines and therapies.

61 Food and Drug Administration (FDA)-approved vaccines are available to combat hemorrhagic fever cause

62 ticularly in Southeast Asia, and no drugs or vaccines are available.

63 Vaccines are being rapidly developed but will likely com

64 Vaccines are important in HPAIV control both for poultry

65 Many livestock and human vaccines are leaky because they block symptoms but do no

66 Vaccines are the most promising solution to mitigate new

67 Highly effective human papillomavirus (HPV) vaccines are used in many national programs in 3- or 2-d

68 We examine both clinically tested vaccines as well as nascent approaches and explore curre

69 fection include both a paucity of protective vaccines as well as the early identification of individu

70 Characteristics of vaccine-associated rash illness (VARI) and confirmed mea

71 We believe that ensilication can improve vaccine availability by enabling transportation without

72 ady infected millions worldwide and, with no vaccine available, interventions to mitigate transmissio

73 face, the development of personalized cancer vaccines based on IR-derived neoepitopes should be consi

74 ority for immunisation should an efficacious vaccine be developed.

75 t that even partial vaccination with a leaky vaccine can have unforeseen positive consequences in con

76 past few decades increasingly suggests that vaccines can also have non-specific effects on unrelated

77 BACKGROUNDThe live attenuated BPZE1 vaccine candidate induces protection against B. pertussi

78 To control TMUV infection, a live-attenuated vaccine candidate of TMUV was developed in our previous

79 A leading vaccine candidate targets 30 of the > 200 emm types of G

80 ough human trials is crucial for advancing a vaccine candidate to clinics.

81 ccinated with a measles-vectored chikungunya vaccine candidate, MV-CHIK, were analyzed.

82 s the leading malaria pre-erythrocytic-stage vaccine candidate.

83 ated to DT protein to provide glycoconjugate vaccine candidates (DT-Hexa, DT-Hepta, and DT-Octa) that

84 trolled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and pote

85 ructure and immunobiology is advancing novel vaccine candidates into human trials.

86 may be useful for generating live attenuated vaccine candidates that prevent disease and fecal spread

87 Testing of vaccine candidates to prevent infection with severe acut

88 vate T-cells indicating that they are cancer vaccine candidates.

89 ch as serosurveillance and the evaluation of vaccine candidates.

90 resent a proton-driven nanotransformer-based vaccine, comprising a polymer-peptide conjugate-based na

91 So far, vaccines containing AMA1 alone have been unsuccessful in

92 ents in effectiveness or VC of the influenza vaccine could lead to substantial additional reductions

93 out vaccine waning and effects of a delay on vaccine coverage suggest it is premature to change curre

94 not account for within-country variation in vaccine coverage, and the optimisation was based on a si

95 urine skin epithelium, enabling epicutaneous vaccine delivery.

96 scular immunisation, GBS67-CpGODN+L formed a vaccine depot at the injection site and induced a remark

97 No vaccine-derived poliovirus variants were detected.

98 tibodies in viral entry and can guide future vaccine design and antibody-based drug therapy.

99 These data provide insight into the vaccine design and evaluation of immunogenicity to enabl

100 cal factors that should not be overlooked in vaccine design and evaluation.IMPORTANCE Differences in

101 ipeline to facilitate use of our dataset for vaccine design and functional annotation of mutations ob

102 hese findings provide new understanding into vaccine design and offer important insight into B cell f

103 However, vaccine design is complicated by concern that elicited a

104 ents in systems immunology, therapeutics and vaccine design should be at the heart of this enterprise

105 Nanotechnology benefits modern vaccine design since nanomaterials are ideal for antigen

106 tention and function may offer a strategy in vaccine design to reduce reactivation and recurrent dise

107 tors working in the areas of drug discovery, vaccine design, and biomedical and biotechnology researc

108 In addition to providing guidance for vaccine design, the antibodies described here are promis

109 le epitope is an important consideration for vaccine design.

110 mmune protection and identifying targets for vaccine design.

111 ed attenuation for next-generation rotavirus vaccine design.

112 ective epitopes that can be used in rational vaccine design.

113 heir findings have important implications to vaccine design.

114 Abs, informing precautions for protein-based vaccines designed to elicit germline versions of neutral

115 which could have important implications for vaccine development against flagellated microbial pathog

116 predictions improve while the lead-time for vaccine development and other interventions decreases.

117 implications of these findings for COVID-19 vaccine development and our approach to optimizing for s

118 s for diagnosis, public health surveillance, vaccine development and the selection of convalescent pl

119 is approach as a potential addition to Ebola vaccine development efforts.IMPORTANCE Ebola outbreaks r

120 and highlight the challenges for successful vaccine development in each phase.

121 al model of the disease, tools to facilitate vaccine development must be identified.

122 ormation for future surveillance, diagnosis, vaccine development, and prediction of EV-D68-associated

123 nderstanding the pathogenesis of SARS-CoV-2, vaccine development, and therapeutic testing.

124 S1 protein may be an alternative antigen for vaccine development, since antibodies to NS1 do not bind

125 e virus in both seasons may be important for vaccine development.

126 algorithms to identify potential targets for vaccine development.

127 ecedented achievement for noninfluenza viral vaccine development.

128 hips of large viruses and should aid in ASFV vaccine development.

129 potential to identify novel drug targets and vaccine development.

130 results highlight the value of ZIKV NS1 for vaccine development.IMPORTANCE Most Zika virus (ZIKV) va

131 HN13 LTA is an attractive target for future vaccine-development studies.

132 Certain assumptions underlie current vaccine developmental strategies, including that infecti

133 The PCS vaccine did not induce immune activation or inflammation

134 s than controls after adjusting for previous vaccine doses (P < .001).

135 estimate the potential contribution of leaky vaccine effect to the observed decline in mVE.

136 es elicited by viral-vectored CSP-expressing vaccines effectively targeted parasites in hepatocytes.

137 3a influenza viruses prompted concerns about vaccine effectiveness (VE) and vaccine strain selection.

138 Vaccine effectiveness (VE) was estimated by conditional

139 ical model to data from studies of influenza vaccine effectiveness (VE), we find that primary infecti

140 RotaTeq vaccine effectiveness among children aged 12-23 months w

141 to determine if our findings directly impact vaccine effectiveness.

142 fluorescent) was compared in vitro and their vaccine efficacy (antigen-specific antibody responses an

143 Vaccine efficacy for vaccinated girls, HE for unvaccinat

144 led human malaria infection (CHMI) to assess vaccine efficacy offer a unique opportunity to study the

145 t-second dose, the primary endpoint (overall vaccine efficacy) was assessed in the first 11 months, a

146 demonstrate that a novel bivalent Ebola VLP vaccine elicits strong humoral and cellular immune respo

147 It is unclear if the flu vaccine exacerbates immune events in patients treated wi

148 odels cannot be used to test the efficacy of vaccines expressing alpha-Gal epitopes because they expr

149 lities do not capture the varied reasons why vaccines fail to advance to regulatory approval.

150 ong measles cases, associated with secondary vaccine failure and modified clinical illness, is emergi

151 Vaccine failure was defined as TBE despite adherence to

152 ination approaches such as the Sanaria PfSPZ Vaccine, followed by controlled human malaria infection

153 troduction of an effective pretravel typhoid vaccine for children <2 years could reduce disease burde

154 ith a case study of Hecolin(R), the licensed vaccine for hepatitis E virus (HEV).

155 t that further development of this candidate vaccine for prevention of EBOV disease is warranted.

156 A safe and effective vaccine for severe acute respiratory syndrome coronaviru

157 e responses to vaccines, including candidate vaccines for HIV.

158 ory, we have not yet succeeded in developing vaccines for some of the world's most deadly diseases, i

159 Since vaccine formulations are given to healthy populations, t

160 tive virus, comparing favorably with several vaccine formulations currently in the clinic.

161 This paper reports the use of the rVSV-ZEBOV vaccine given as an emergency intervention to individual

162 igen was noted in lungs of animals in either vaccine group.

163 ers to H1N1 were similar among the different vaccine groups.

164 To date, no drug or vaccine has been approved to treat the severe disease ca

165 Capsule-targeted pneumococcal vaccines have likely contributed to increased carriage o

166 mals given SARS or MERS vaccines resulted in vaccine hypersensitivity reactions (VAH), similar to tho

167 k) following trivalent influenza inactivated vaccine (IIV3) immunization in pregnant women, and assoc

168 d (trivalent high-dose inactivated influenza vaccine [IIV3-HD], or quadrivalent recombinant influenza

169 neutralizing antibodies and the template for vaccine immunogen design.

170 ory vaccine adjuvant may influence RhCMV/SIV vaccine immunogenicity and efficacy.

171 ed, JENVAC to the live-attenuated SA 14-14-2 vaccine in healthy children.

172 understand how to monitor immune response to vaccines in immunosuppressed patients and when to optima

173 Despite the overwhelming success of vaccines in preventing infectious diseases, there remain

174 ng elephants and responses to candidate EEHV vaccines in the future.IMPORTANCE Whether clinical illne

175 Indeed, although nearly all vaccines in use today depend on their ability to induce

176 has been used to enhance immune responses to vaccines, including candidate vaccines for HIV.

177 As global availability of rotavirus vaccines increases, recent studies have assessed whether

178 mtdVSV-NS1-based vaccine or two doses of DNA vaccine induced high levels of NS1-specfic antibody and

179 results underlie the importance of balanced vaccine-induced activating versus suppressive immune res

180 Vaccine-induced antibodies exhibit a high degree of clon

181 ent modulation of T(fh) cells enhances HIV-1 vaccine-induced antienvelope (anti-Env) antibody respons

182 ow that autophagy is specifically induced in vaccine-induced antigen-specific CD8+ T cells in healthy

183 Additionally, vaccine-induced CD8 T cells poorly cross-recognized vari

184 The vaccine-induced T cells had a cytotoxic phenotype and we

185 To help inform vaccine introduction, the Surveillance for Enteric Fever

186 s investigated in a phase 2A study of RV3-BB vaccine involving 46 individuals in Dunedin, New Zealand

187 routine immunization with inactivated polio vaccine (IPV), to ensure type 2 immunity.

188 mated by an NFDS-based model at the time the vaccine is introduced, enables us to predict whether the

189 Since it is unknown whether influenza vaccine is leaky, we simulated the 2011-2012 to 2014-201

190 If a SARS-CoV-2 vaccine is licensed within 18 months of the start of the

191 with COVID-19, developing effective and safe vaccines is a top research priority.

192 e that features an overview of the COVID-19 'vaccine landscape', a clinical trials database and a 'li

193 ain dominated and there was a good antigenic vaccine match.

194 ndividual bats, implying that DrBHV-vectored vaccines might invade despite the highly prevalent wild-

195 Safe and effective COVID-19 vaccines must avoid VAH.

196 healthy adult participants to the adjuvanted vaccine (n=17), vaccine alone (n=16), or placebo group (

197 ninferiority trial was conducted among polio vaccine-naive Cuban infants who received 2 IPV doses at

198 is is involved in the nonspecific effects of vaccines on mortality.

199 plore its potential use as a live-attenuated vaccine or a vaccine vector for the treatment of other v

200 cal disease in some individuals, there is no vaccine or cure.

201 and then further randomly assigned to either vaccine or placebo.

202 d to enhance the efficacy of an EBV-specific vaccine or treat severe EBV infection and pathological c

203 In the absence of a universal influenza A vaccine or treatment, influenza A will remain a signific

204 A single dose of mtdVSV-NS1-based vaccine or two doses of DNA vaccine induced high levels

205 Currently, there are no FDA-approved vaccines or therapeutics available to combat VEEV infect

206 for their implementation as live-attenuated vaccines or vaccine vectors.IMPORTANCE To date, no Food

207 evastating diseases without fully protective vaccines, particularly human immunodeficiency virus (HIV

208 en reported following pneumococcal conjugate vaccine (PCV) implementation.

209 in a double-blind, placebo-controlled trial (vaccine-placebo ratio, 2:1) at 106 plaque-forming units

210 We demonstrate the construction of a vaccine platform based on a unique three-plasmid system

211 Virus-like particles (VLPs) are important vaccine platforms against pathogenic threats, including

212 uenza vaccines while developing entirely new vaccine platforms.

213 we are able to forecast the equilibrium post-vaccine population composition and assess the invasion c

214 fatal neurological disease, but morbidity is vaccine preventable and treatable prior to the onset of

215 lla pertussis is among the leading causes of vaccine-preventable deaths and morbidity globally.

216 ich may leave communities more vulnerable to vaccine-preventable diseases.

217 Vaccination with both vaccines prevented fever and protected against abortion.

218 University; Cambridge, MA, USA) and Janssen Vaccines & Prevention (Leiden, Netherlands).

219 Bill & Melinda Gates Foundation, and Janssen Vaccines & Prevention.

220 undergo adaptive mutations during egg-based vaccine production.

221 For example, vaccines rarely provide perfect immunity.

222 Vaccine recipients received ALVAC-HIV (vCP2438) alone at

223 through to the end of follow-up, contrasting vaccine recipients with different values of the immune r

224 ity and polyfunctionality scores relative to vaccine recipients with no late boost (all adjusted p<0.

225 ge suggest it is premature to change current vaccine recommendations, although it may be prudent to p

226 Ankara vectors to generate a viral-vectored vaccine, referred to as Nous-209.

227 Here, we tested a vaccine regimen in pigtail macaques using an intranasal

228 We investigated two SIV vaccine regimens combining mucosal priming immunizations

229 No severe vaccine-related adverse events were reported.

230 No vaccine-related serious adverse effects were found in th

231 All vaccines rely on the ability of B cells to remember path

232 njectable, tetravalent inactivated influenza vaccines replacing IIV3.

233 Influenza vaccines represent the most effective response to this t

234 evelopment.IMPORTANCE Most Zika virus (ZIKV) vaccine research has focused on the E or prM-E proteins

235 gdom Medical Research Council Studentship in Vaccine Research, Innovative Medicines Initiative 2 Join

236 ulin G increased >=4-fold in 95% and 100% of vaccines, respectively.

237 ere unabated, despite a blocked anti-insulin vaccine response in SAP-deficient NOD mice.

238 entiating T cells can be targeted to improve vaccine responses, in particular in older individuals wh

239 a 12-month booster of subtype C pox-protein vaccines restored immune responses, and slowed response

240 irus challenge of animals given SARS or MERS vaccines resulted in vaccine hypersensitivity reactions

241 3-HD], or quadrivalent recombinant influenza vaccine [RIV4]), safety and immunogenicity trial of qNIV

242 ion between HBGA status and G3P[6] rotavirus vaccine (RV3-BB) take was investigated in a phase 2A stu

243 the "outbreak strain") were determined, and vaccine safety was evaluated.

244 rformance of differing PCV schedules against vaccine-serotype colonization in children.

245 <5 years of age, frequency and diversity of vaccine serotypes (VTs) decreased significantly post-PCV

246 DBA/2J mice vaccinated with COBRA vaccines showed increase survival for all three viral ch

247 lizing derivations to allow for time-varying vaccine status, including out-of-season controls, and op

248 est) against both the Jeryl Lynn mumps virus vaccine strain (hereafter, the "vaccine strain") and the

249 We find that this vaccine strain elicits antibodies that have reduced reac

250 oncerns about vaccine effectiveness (VE) and vaccine strain selection.

251 mumps virus vaccine strain (hereafter, the "vaccine strain") and the MuVi/Utrecht.NLD/40.10 outbreak

252 The impact of implementing different vaccine strategies for immunocompetent adults comparing

253 nd provide actionable information for use in vaccine studies.

254 e have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein

255 show that high-affinity vaccines targeting rare B cells capable of broadly prote

256 Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries.

257 As typhoid conjugate vaccine (TCV) is rolled out, surveillance should continu

258 zation now recommends that typhoid conjugate vaccines (TCV) be used in settings with high typhoid inc

259 tanus-diphtheria-pertussis inactivated polio vaccine (Tdap) 3 months later; BCG and Tdap combined; or

260 For vaccine testing, an easily accessible cell platform woul

261 igher total IgG titres after the tetravalent vaccine than after the trivalent vaccine (10 413 EU/mL,

262 fector CD8(+) T cells or immunization with a vaccine that induces virus-specific effector CD8(+) T ce

263 e 4CMenB is a new, recombinant protein-based vaccine that is licensed to protect against invasive gro

264 Developing improved vaccines that elicit broader immunity remains a public h

265 r the resurrection of previous drug of abuse vaccines that have met limited success in the past.

266 throcytes, PfGARP could synergize with other vaccines that target parasite invasion of hepatocytes or

267 tiviral drugs and broadly reactive influenza vaccines that target the HA protein have suffered resist

268 the herpes simplex virus 1 (HSV-1) 0DeltaNLS vaccine, the correlate of protection has been defined to

269 e is a desperate need for safe and effective vaccines, therapies, and diagnostics for SARS- coronavir

270 mbinant major outer membrane protein (rMOMP) vaccine to elicit cross-serogroup protection.

271 RS-CoV-2), while striving to find a suitable vaccine to immunize healthy individuals.

272 ate to the rapid "Warp Speed" development of vaccines to counter the COVID-19 pandemic.

273 to the evaluation of potential therapies and vaccines to inhibit SARS-CoV-2 infection and ameliorate

274 'living review' that distils the results of vaccine trials as they become available.

275 rrelates of protection that may guide future vaccine trials.

276 Few studies have applied this knowledge to vaccine trials.

277 We found significant VE against vaccine-type CIN2+ after 3 doses of HPV vaccine and lowe

278 coverage, and underwent a linear decrease in vaccine uptake, from 92% to 70% over 15 years.

279 ues in the CTL epitope presentation pathway: vaccine uptake, phagolysosomal escape, and epitope relea

280 fety assessments are important in sustaining vaccine uptake.

281 that impacted protection, regardless of the vaccine used.

282 ential use as a live-attenuated vaccine or a vaccine vector for the treatment of other viral infectio

283 pire bat betaherpesvirus (DrBHV) to act as a vaccine vector.

284 how that strain 68-1 rhesus macaque (RM) CMV vaccine vectors expressing HBV Ags engender HBV-specific

285 mplementation as live-attenuated vaccines or vaccine vectors.IMPORTANCE To date, no Food and Drug Adm

286 uriously, the clade containing the lapinised vaccine viruses that were developed originally in Korea

287 Uncertainties about vaccine waning and effects of a delay on vaccine coverag

288 h regions using PCV13 vs regions using PPV23 vaccine was also analyzed for 2017-2019.

289 ber of 31 FSPs out of the 209 encoded by the vaccine was detected both in DNA and mRNA extracted from

290 e prevalence of the 7 HR-HPV types in the 9v vaccine was high and was associated with abnormal cytolo

291 The vaccine was relatively well tolerated, but a high percen

292 etastatic gastrointestinal cancer.RESULTSThe vaccine was safe and elicited mutation-specific T cell r

293 To enable a new generation of anti-viral vaccines, we designed self-assembling protein nanopartic

294 The HPV types included in the quadrivalent vaccine were detected in 1002 (14.8%) specimens, with a

295 , S195D and M217T in relation to the RotaTeq vaccine were radical in nature and resulted in a change

296 ly dedicated to improving seasonal influenza vaccines while developing entirely new vaccine platforms

297 ventions, it is believed that only effective vaccines will provide sufficient control over the diseas

298 Of these constructs, the chimeric HA (cHA) vaccine with consensus H5 as globular head and consensus

299 Biopharmaceuticals, e.g. liquid-formulated vaccines with adjuvants, frequently have poor thermal st

300 appreciable interchangeability between both vaccines, with JENVAC/JENVAC combination exhibiting the